Cyclodextrin

The CAVADEX® molecule


CAVADEX® (developed by Cholrem Pty Ltd) is a form of Hydroxypropyl beta cyclodextrin (HPßCD) that is comprised of seven sugar molecules bound together in a ring (cyclic oligosaccharide).

The ring-shaped, three-dimensional structure has a hydrophobic cavity in its center, which is capable of trapping cholesterol and lipids. It has been used extensively as an excipient in the food, deodorant, and drug industry for the past century, and it is generally recognized as safe (GRAS).

As an active ingredient, CAVADEX® entraps and removes intracellular cholesterol and lipids that can cause injury to the kidneys and other organs, including the brain and liver.

blog-post blog-post

Cyclodextrin harmlessly absorbs cholesterol from cells

blog-post

Mice artery showing substantial reduction in plaque

German scientists discover treatment to remove plaque


In 2016 a team of scientists from Germany's Bonn University discovered a new compound that reduced plaque in mice by over 40% in as little as 4 weeks.

The new cyclodextrin compound (CAVADEX®) was also tested on human plaque and they discovered it affected the plaque in a similar way.

breakthrough discovery !!


Link to the published article



CAVADEX® entraps and removes harmful cholesterol from plaque

blog-post



Related Articles


"Cyclodextrin reprogrammed the cells in plaques, leading to increased transport of the dissolved cholesterol away from the plaques..."

nature.com : Molecule melts away cholesterol.


"Cyclodextrin dissolves cholesterol crystals and reduces atherosclerotic plaques..."

sciencedaily.com : Drug used for rare disease may be able to treat heart disease.


"Soaked up cholesterol and removed it..."

sciencedaily.com : New hope for treating atheriosclerosis


"have the potential in lowering deaths caused by atherosclerosis..."

ntnu.co : Can a sugar treat atherosclerosis?


"can actually solubilize cholesterol and dissolve the plaques..."

huffpost.com : Cholesterol sweet spot.




Research studies


"Alzheimer disease"
A study on the effects of HP-B-CD in transgenic mice with Alzheimer disease showed a dramatic reduction in symptoms and significantly improved spatial learning and memory deficits in mice. The study concluded HP-B-CD could be a novel therapeutic strategy for Alzheimer disease.



"Diabetic kidney disease"
HP-B-CD has shown promising pre-clinical results in kidney disease. Progression of kidney disease was prevented in mouse models and diabetic kidney disease was prevented or partially prevented in two pre-clinical studies.



"Non-alcoholic fatty liver disease"
Several studies have shown that HP-B-CD reduces liver cholesterol and cholesterol crystals. HP-B-CD has a substantial effect on cholesterol distribution and cholesterol transporters.



"Improved eyesight"
Lipofuscin accumulation in the retinal pigment epithelium is a hallmark of aging. A study was done on the effects of cyclodextrin and found that the beta-cyclodextrin can bind retinal lipofuscin, prevent its oxidation and remove it.
Cholrem patients have also reported improved vision after treatments of CAVADEX®.




CAVADEX® removes plaque and cholesterol

plaque reduced in just 4 weeks

A recent study by the University Hospital in Bonn, Germany discovered that cyclodextrin melts away cholesterol crystals (the main cause of arterial plaque that clogs arteries) and reduced existing plaque within just 4 weeks. The cyclodextrin bound to and dissolved the cholesterol crystals from the plaque of mice, leading to transport of the dissolved cholesterol away from the plaques. The same effects were seen in human plaque samples treated with cyclodextrin.

Article : Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming

Improve Liver function

Another study by the University of Texas Southwestern Medical Center, Dallas, Texas, shows the treatment of Npc1-deficient mice slows cholesterol sequestration in major organs and improves liver function. This study shows that cyclodextrin is effective in mobilizing entrapped cholesterol in late stage NPC disease leading to improved liver function.

Article : Systemic administration of 2-hydroxypropyl-B-cyclodextrin to symptomatic Npc1-deficient mice slows cholesterol sequestration in the major organs and improves liver function.




Cyclodextrin Publications


About Cyclodextrins

Molecular mechanism of cyclodextrin mediated cholesterol extraction


Rationale for Therapeutic Use of Lipid Transport Mediators in Renal Disease

Local TNF causes NFATc1-dependent cholesterol-mediated podocyte injury.

Systemic and renal lipids in kidney disease development and progression 

Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.

Lipid biology of the podocyte--new perspectives offer new opportunities.

Renal lipid metabolism and lipotoxicity. 


Cyclodextrins and Non-renal Diseases

Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming.

Weekly Treatment of 2-Hydroxypropyl-β-cyclodextrin Improves Intracellular Cholesterol Levels in LDL Receptor Knockout Mice.

Beta cyclodextrins bind, stabilize, and remove lipofuscin bisretinoids from retinal pigment epithelium.

Neuroprotection by cyclodextrin in cell and mouse models of Alzheimer disease.


Cyclodextrins and Renal Disease

Cyclodextrin Protects Podocytes in Focal Segmental Glomerulosclerosis (FSGS)

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.

Cyclodextrin improves renal function in experimental alport syndrome.

Cyclodextrin protects podocytes in diabetic kidney disease.